AIM ImmunoTech signed an agreement with PPD for a Phase 3 trial of Ampligen for late-stage pancreatic cancer treatment.
In a press release dated March 2nd, 2026, AIM ImmunoTech Inc. disclosed a partnership with the PPD™ clinical research unit of Thermo Fisher Scientific to develop a Phase 3 clinical trial for their drug Ampligen. This trial aims to explore the efficacy of Ampligen in treating advanced pancreatic cancer. AIM ImmunoTech Inc., listed on the NYSE American as AIM, is undertaking this collaboration to advance their research efforts in this critical area of oncology.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments